Liver Impact Thickens Plot for AstraZeneca Blood Thinner
Despite its benefits, warfarin is awkward for patients because it requires them to take periodic blood tests to make sure the drug's anti-clot-forming effort is successful. (Clinical trials show patients can take a fixed dose of Exanta, thus avoiding the constant blood-testing.)
If the warfarin effect is too great, patients can suffer from internal bleeding or other bleeding, such as from the gums during brushing. If the impact is too little, patients remain vulnerable to clots. In addition, warfarin interacts with many drugs, herbal medications and foods that can exacerbate or depress the blood thinner's effect. Exanta has fewer interactions with other products.
AstraZeneca began marketing Exanta in Germany on June 21, having secured European Union regulatory approval in late 2003 for preventing blood clots in patients who had undergone elective hip or knee replacement surgeries. This is a narrow use of the drug, but it's also one for which liver problems would be less likely to arise because patients won't take the drug for a long time. The EU approval calls for the drug to be administered orally for 11 days.
However, the big market -- and big controversy -- will be in chronic uses, such as atrial fibrillation or the installation of a mechanical heart valve. These patients would have to take Exanta for the rest of their lives. AstraZeneca is seeking European Union approval for expanded applications of the drug.AstraZeneca is seeking FDA approval for three uses: preventing blood clots in veins for patients undergoing knee replacement surgery; preventing stroke and other clot-induced complications of atrial fibrillation; and long-term prevention of blood clots in veins after a patient has gotten a standard blood clot treatment. AstraZeneca, which submitted its FDA application in late December, is seeking approval based on tests involving more than 30,000 patients. Exanta clinical trial results have appeared in such prestigious publications as The New England Journal of Medicine and The Lancet as well as at major cardiology conferences.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV